NASDAQ : MBX
MBX Biosciences, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 55.87 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.69B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 29.73M | 19.20M | 10.98M | 6.98M | 3.86M |
| Research & Development | 88.19M | 78.86M | 57.22M | 28.33M | 21.30M |
| Operating Expenses | 117.92M | 98.06M | 68.19M | 35.31M | 25.16M |
| Operating Income | -117.92M | -98.06M | -68.19M | -35.31M | -25.16M |
| Interest Expense | -374.00K | ||||
| Interest & Investment Income | 11.34M | 7.47M | 3.34M | 1.70M | 345.00K |
| Other Non Operating Income (Expenses) | -73.00K | ||||
| EBT Excluding Unusual Items | -106.58M | -90.58M | -64.85M | -33.61M | -25.26M |
| Gain (Loss) on Sale of Investments | 2.29M | 3.61M | 2.93M | 1.04M | 27.00K |
| Other Unusual Items | -899.00K | ||||
| Pretax Income | -104.29M | -86.97M | -61.92M | -32.56M | -26.14M |
| Net Income | -104.29M | -86.97M | -61.92M | -32.56M | -26.14M |
| Net Income to Common | -104.29M | -86.97M | -61.92M | -32.56M | -26.14M |
| Shares Outstanding (Basic) | 43.36M | 36.51M | 10.64M | 1.02M | 667.02K |
| Shares Outstanding (Diluted) | 43.36M | 36.51M | 10.64M | 1.02M | 667.02K |
| EPS (Basic) | -2.41 | -2.38 | -5.82 | -31.96 | -39.18 |
| EPS (Diluted) | -2.41 | -2.38 | -5.82 | -31.96 | -39.18 |
| Free Cash Flow | -85.20M | -81.88M | -55.55M | -32.11M | -23.56M |
| Free Cash Flow Per Share | -1.97 | -2.24 | -5.22 | -31.52 | -35.33 |
| EBITDA | -117.66M | -97.81M | -67.95M | -35.15M | -25.11M |
| D&A For EBITDA | 253.00K | 248.00K | 244.00K | 157.00K | 56.00K |
| EBIT | -117.92M | -98.06M | -68.19M | -35.31M | -25.16M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 54.12M | 75.29M | 49.35M | 30.52M | 24.21M |
| Short-Term Investments | 364.46M | 298.42M | 212.80M | 50.15M | 18.25M |
| Cash & Short-Term Investments | 418.58M | 373.70M | 262.15M | 80.68M | 42.46M |
| Other Receivables | 3.04M | 2.12M | 682.00K | 208.00K | 142.00K |
| Receivables | 3.04M | 2.12M | 682.00K | 208.00K | 142.00K |
| Prepaid Expenses | 5.07M | 4.85M | 3.65M | 2.45M | 1.52M |
| Other Current Assets | 1.16M | 861.00K | 803.00K | 133.00K | 84.00K |
| Total Current Assets | 427.86M | 381.54M | 267.29M | 83.47M | 44.21M |
| Property, Plant & Equipment | 7.42M | 3.22M | 1.20M | 665.00K | 842.00K |
| Other Long-Term Assets | 247.00K | 383.00K | 50.00K | 50.00K | 42.00K |
| Total Assets | 435.91M | 385.14M | 268.54M | 84.18M | 45.09M |
| Accounts Payable | 4.36M | 2.98M | 5.33M | 1.39M | 976.00K |
| Accrued Expenses | 18.67M | 12.35M | 5.54M | 2.38M | 2.32M |
| Current Portion of Leases | 631.00K | 172.00K | 171.00K | 153.00K | 137.00K |
| Total Current Liabilities | 23.66M | 15.49M | 11.05M | 3.93M | 3.43M |
| Long-Term Leases | 2.71M | 424.00K | 171.00K | 324.00K | |
| Other Long-Term Liabilities | 2.00K | 42.00K | 194.00K | 66.00K | |
| Total Liabilities | 26.37M | 15.92M | 11.09M | 4.29M | 3.82M |
| Common Stock | 6.00K | 6.00K | 5.00K | 1.00K | 1.00K |
| Additional Paid-In Capital | 695.84M | 593.41M | 394.89M | 3.05M | 411.00K |
| Retained Earnings | -285.09M | -224.48M | -137.50M | -75.58M | -43.02M |
| Comprehensive Income & Other | -1.22M | 286.00K | 55.00K | 60.00K | 3.00K |
| Total Common Equity | 409.54M | 369.22M | 257.44M | -72.47M | -42.60M |
| Shareholders' Equity | 409.54M | 369.22M | 257.44M | 79.89M | 41.27M |
| Total Liabilities & Equity | 435.91M | 385.14M | 268.54M | 84.18M | 45.09M |
| Total Debt | 3.34M | 596.00K | 171.00K | 324.00K | 461.00K |
| Net Cash (Debt) | 415.24M | 373.11M | 261.98M | 80.35M | 42.00M |
| Net Cash Per Share | 9.58 | 10.22 | 24.62 | 78.87 | 62.97 |
| Filing Date Shares Outstanding | 48.16M | 47.51M | 33.42M | 1.26M | 667.02K |
| Total Common Shares Outstanding | 47.95M | 44.93M | 33.42M | 1.26M | 667.02K |
| Working Capital | 404.20M | 366.04M | 256.24M | 79.54M | 40.78M |
| Book Value Per Share | 8.54 | 8.22 | 7.70 | -57.65 | -63.87 |
| Tangible Book Value | 409.54M | 369.22M | 257.44M | -72.47M | -42.60M |
| Tangible Book Value Per Share | 8.54 | 8.22 | 7.70 | -57.65 | -63.87 |
| Machinery | 2.25M | 1.27M | 1.11M | 242.00K | 227.00K |
| Construction In Progress | 2.55M | 1.62M | 3.00K | ||
| Leasehold Improvements | 677.00K | 520.00K | 391.00K | 372.00K | 350.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -104.29M | -86.97M | -61.92M | -32.56M | -26.14M |
| Depreciation & Amortization | 353.00K | 348.00K | 244.00K | 157.00K | 56.00K |
| Loss (Gain) From Sale of Assets | 69.00K | ||||
| Loss (Gain) From Sale of Investments | -2.29M | -3.61M | -2.93M | -1.04M | -27.00K |
| Stock-Based Compensation | 16.45M | 8.68M | 5.22M | 2.04M | 306.00K |
| Other Operating Activities | 118.00K | 33.00K | 106.00K | 95.00K | 1.39M |
| Change in Accounts Payable | -2.16M | -2.46M | 3.93M | 412.00K | 671.00K |
| Change in Other Net Operating Assets | 9.15M | 4.03M | 670.00K | -1.15M | 619.00K |
| Operating Cash Flow | -82.67M | -79.95M | -54.68M | -31.98M | -23.12M |
| Capital Expenditures | -2.53M | -1.93M | -874.00K | -129.00K | -441.00K |
| Investment in Securities | -178.27M | -81.78M | -159.72M | -30.80M | -10.97M |
| Investing Cash Flow | -180.80M | -83.70M | -160.59M | -30.93M | -11.41M |
| Short-Term Debt Issued | 10.00M | ||||
| Total Debt Issued | 10.00M | ||||
| Net Debt Issued (Repaid) | 10.00M | ||||
| Issuance of Common Stock | 279.29M | 190.36M | 174.94M | 739.00K | 30.00K |
| Other Financing Activities | -1.28M | -771.00K | -4.34M | -30.00K | -458.00K |
| Financing Cash Flow | 278.02M | 189.59M | 234.10M | 69.22M | 46.06M |
| Net Cash Flow | 14.55M | 25.94M | 18.83M | 6.31M | 11.53M |
| Free Cash Flow | -85.20M | -81.88M | -55.55M | -32.11M | -23.56M |
| Free Cash Flow Per Share | -1.97 | -2.24 | -5.22 | -31.52 | -35.33 |
| Levered Free Cash Flow | -53.01M | -52.44M | -33.27M | -20.56M | |
| Unlevered Free Cash Flow | -53.01M | -52.44M | -33.27M | -20.56M | |
| Change in Working Capital | 6.99M | 1.57M | 4.60M | -735.00K | 1.29M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 2.69B | 1.42B | 615.88M | ||
| Enterprise Value | 2.28B | 1.03B | 339.03M | ||
| Last Close Price | 55.87 | 31.54 | 18.43 | ||
| PB Ratio | 6.54 | 3.84 | 2.39 | ||
| P/TBV Ratio | 6.57 | 3.84 | 2.39 | ||
| Debt / Equity Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 |
| Net Debt / Equity Ratio | -1.01 | -1.01 | -1.02 | -1.01 | -1.02 |
| Net Debt / EBITDA Ratio | 3.53 | 3.81 | 3.85 | 2.29 | 1.67 |
| Net Debt / FCF Ratio | 4.87 | 4.56 | 4.72 | 2.50 | 1.78 |
| Quick Ratio | 17.82 | 24.25 | 23.78 | 20.60 | 12.42 |
| Current Ratio | 18.08 | 24.62 | 24.19 | 21.26 | 12.89 |
| Return on Equity (ROE) | -33.17% | -27.76% | -36.71% | -53.75% | |
| Return on Assets (ROA) | -22.08% | -18.75% | -24.17% | -34.14% | |
| Return on Capital Employed (ROCE) | -28.60% | -26.50% | -26.50% | -44.00% | -60.40% |
| Earnings Yield | -4.30% | -6.14% | -10.05% | ||
| FCF Yield | -3.17% | -5.78% | -9.02% | ||
| Buyback Yield / Dilution | -62.14% | -243.01% | -944.70% | -52.73% |